Articles
| Open Access |
DOI: The Role Of Leptin And Adiponectin In Disorders Of Fatter Tissue In Metabolic Syndrome
Nelli Rafikovna Uzbekova , Professor, Candidate Of Medical Sciences, Andijan State Medical Institute, UzbekistanAbstract
In this article, opinions were expressed on the improvement of early-stage diagnostic factors and the optimal pathways of therapeutic treatment, having determined the characteristics of heterogeneous neurohumorals of metabolic syndrome, the clinical manifesto of the disease. The analysis of the study shows that the issues of pathogenesis, clinical features of improving the effectiveness of medicamentous therapy, and treatment-rehabilitation aspects have not been studied perfectly so far. In patients with metabolic syndrome, hypotensive, anti-adipose agents, as well as treatment of statins and improvement of the prophylactic order of prevention of diseases, the issues of which were not studied at the end were discussed.
Keywords
The hormone, adiponectin, tissue, , metabolic syndrome
References
Uzbekova N.R. Modern concepts of insulin-like growth factors in normal conditions and their role in diabetes mellitus . Volume: 02 Issue: 02 | March-April 2021 ISSN: 2660-4159 pp.236-239.
www.cajmns.centralasianstudies.org/index.php
Uzbekova N.R. Neuro humoral mechanisms of the pathogenesis of the metabolic syndrome and ways of their therapeutic correction. Abstract of doctoral (DsC) dissertation on medical sciences. 2017 year.
Bagdade J.D., Buchanan W.F., Pollare T., LithellH.Abnormal lipoprotein phospholidip composition in patients with essential hypertension // Atherosclerosis 2009.-117: pp.209-215 .
Bruns M.W., Hall J.E. Hyperinsulinemia and hypertonia. NMCD 2003; 3: pp.155-157.
Despres J.P. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients risk. Obesity Res. 2008; 6: pp.89-179.
Esler M., Rumanier., Wiesner G. et al. Sympathetic nervous system and insylin resistance. From obesite to diabetes // Am. J. Hypertens. 2008- 14: pp.304-309.
Camus J. Goutte, diabete, hyperlipemie: un trisyndrome metaboliqul. Rev Rhumat. 2006; 33:pp.10-14.
Cusi K., Defronzo R.A. Metgormin: a revien of its metabolic effects. Diabetes Reviews. 2004; 6: pp.89-131.
Reaven G. M. Insulin resistance/compensatory hyperinsulinimia, essential hypertension, and cardiovascular disease. J. ClinEndocrindMetab. 2007;
Heseeler J.R., Morel D.W., Leves J., Chisolm G.M., Lipoprotens oxidation and lipoprotein-indused cytotoxicity. // Atherosclerosis. 2006; 3: pp215-222
Froze E. Age related changes in postprandial plasma glucose, insulin and FFA concentrations in non-diabetic individuals / E. Froze, M. Chiou, Y. Chen, G.M. Raeven // J Am Geriatr Soc.-2011.- Vol. 35,- pp. 224-228.
Furchgott R.F. The obligatoryrole of endotnelial cells in the relazation of arterial smooth muscle by acetylcholine / R.F. Furchgott, J.V. Zawadszki // Nature.- 2009.- Vol. 288.- pp. 373-376.
Anize Delfino von Frankenberg. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review.
http://www.scielo.br/scielo.php?script=sci_serial&pid=2359-3997&lng=en&nrm
issn 2359-4292. 2017 year
Article Statistics
Copyright License
Copyright (c) 2021 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.